Loading...
Loading...
BDSX| Name | Value |
|---|---|
| Revenues | 14.8M |
| Cost of Revenue | 3.2M |
| Gross Profit | 11.6M |
| Operating Expense | 22.6M |
| Operating I/L | -11.0M |
| Other Income/Expense | -2.6M |
| Interest Income | 0.0M |
| Pretax | -13.6M |
| Income Tax Expense | 1.3M |
| Net Income/Loss | -13.6M |
Biodesix, Inc. is a data-driven diagnostic solutions company in the United States, specializing in blood-based lung tests. Their Nodify XL2 and Nodify CDT tests, marketed as part of Nodify Lung Nodule Risk Assessment, assess the risk of lung cancer and aid in treatment decisions. They also offer GeneStrat ddPCR and VeriStrat tests for lung cancer diagnosis and prognosis, as well as GeneStrat NGS test. Additionally, through a partnership with Bio-Rad Laboratories, Inc., they provide COVID-19 testing under the Biodesix WorkSafe program. The company generates revenue through the sale of diagnostic tests, clinical research and trial testing services, and companion diagnostics.
